Abstract Library

#1864 Analysis of mTOR, CXCR4 and PD-1 Checkpoint Pathways in Merkel Cell Neuroendocrine Carcinomas: Correlations with Prognosis and Viral Status

Introduction: Merkel cell carcinoma (MCC) is a rare and aggressive cutaneous neuroendocrine tumor. Prognostic factors currently included in the reference AJCC classification are mainly clinical.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Benhamou J, Deschamps L, Vergier B, Pham-Ledard A, Carlotti A,

Keywords: Merkel cell carcinoma, mTor, CXCR4, PD-L1,

#1377 Metastatic Neuro Endocrine Tumors: Epidemiological Characteristics, Management and Prognostics Factors. Results from an Inter-Regional Network in France between Upper and Lower Normandy

Introduction: Metastatic neuro-endocrine tumors (MNETs) are rare and their management are complex. To standardize therapeutic strategies in France, a national network of clinicians (RENATEN) has been created, composed of 17 expert centres.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Lesouef M, Bouhier-Leporier K, Pham A, Granier S, Dupont B,

Keywords: Metastatic Neuro-Endocrine Tumors, Epidemiological Characteristics,

#1211 Lack of Efficacy of Anthracycline-Containing Second Line Chemotherapy in Patients with GI-NEC After Cisplatin-Based Treatment

Introduction: Little is known about optimal 2nd-line treatment in patients with GI-NEC failing cisplatin-based therapy.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Kiesewetter B, Koparek O, Mayerhoefer M, Niederle B, Raderer M,

Keywords: GI-NEC,

#744 Bio-Differentiating and Antiangiogenic Therapy with Gastroenteropancreatic Patients with Neuroendocrine Tumors (GEP-NETs)

Introduction: The outcome of patients with metastatic, progressive or recurrent neuroendocrine tumors remains poor despite the several novel therapeutic approaches.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Holubec L

Authors: Holubec L, Finek J, Fiala O, Matejka V, Dreslerova J,

Keywords: GEP-NET, experimental metronomic therapy, tumor marker,

#322 Effect of mTOR Inhibitor and Octreotide LAR on the Vascularization of Hepatic Metastases of Non-Pancreatic NETs: Preliminary Semi-Quantitative Dynamic MRI Assessment

Introduction: mTOR inhibitor Everolimus is a promising treatment in advanced NET. Its mechanisms include an antiangiogenic effect. Dynamic-enhanced MRI (D-MRI) enables the in vivo evaluation of tumoral perfusion.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Pham C, E. B, C. C, J. G, F. B,

Keywords: neuroendocrine tumor, mTOR, everolimus, octreotide, vascularisation, MRI,